OncoSil Medical Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

OncoSil Medical şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-11.4%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-11.4%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

How Much Did OncoSil Medical's(ASX:OSL) Shareholders Earn From Share Price Movements Over The Last Year?

Dec 04

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: OSL şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: OSL şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

OncoSil Medical Piyasaya Karşı Temettü Getirisi

OSL temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (OSL)	n/a
Pazarın Alt %25'i (AU)	2.6%
Pazarın En İyi %25'i (AU)	6.0%
Sektör Ortalaması (Life Sciences)	0.6%
Analist tahmini (OSL) (3 yıla kadar)	0%

Önemli Temettü: OSL şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, OSL şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: OSL şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: OSL herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

OncoSil Medical Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

OncoSil Medical Limited has filed a Follow-on Equity Offering in the amount of AUD 1 million.

OncoSil Medical Limited, Annual General Meeting, Nov 20, 2024

Full year 2024 earnings released: AU$0.005 loss per share (vs AU$0.01 loss in FY 2023)

Peter Hall Elects Not to Join Oncosil Medical Limited's Board

Full year 2024 earnings released: AU$0.006 loss per share (vs AU$0.01 loss in FY 2023)

OncoSil Medical Limited Appoints Peter Hall as Non-Executive Director

OncoSil Medical Limited has filed a Follow-on Equity Offering in the amount of AUD 2.7 million.

New major risk - Market cap size

OncoSil Medical Limited has filed a Follow-on Equity Offering in the amount of AUD 1.48 million.

New major risk - Market cap size

Oncosil Medical Limited Elects Gabrielle Liberatore as Director

New major risk - Market cap size

New major risk - Share price stability

OncoSil Medical Limited, Annual General Meeting, Nov 29, 2023

Full year 2023 earnings released: AU$0.01 loss per share (vs AU$0.013 loss in FY 2022)

OncoSil Appoints Gabriel Liberatore to the Board

OncoSil Medical Limited Announces Appointment of Dal Cin as Chief Financial Officer

Oncosil Medical Ltd Announces Resignation of Karl Pechmann as Chief Financial Officer

Insider recently bought AU$1.2m worth of stock

First half 2023 earnings released: AU$0.006 loss per share (vs AU$0.007 loss in 1H 2022)

Oncosil Medical Limited Announces Two Key Treatment Centres Treat First Patients with Oncosil

OncoSil Medical Limited has completed a Follow-on Equity Offering in the amount of AUD 6.09495 million.

Forecast to breakeven in 2025

Less than half of directors are independent

OncoSil Medical Limited Announces Resignation of Martin Cross as Director

OncoSil Medical Ltd Appoints Brian Leedman to the Board as a Non-Executive Director

Forecast to breakeven in 2025

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

OncoSil Medical Limited, Annual General Meeting, Oct 25, 2022

Oncosil Medical Ltd Announces Second Patient Treated in Spain Proceeds to Successful Resection

Companies Like OncoSil Medical (ASX:OSL) Could Be Quite Risky

Less than half of directors are independent

OncoSil Medical Ltd. Announces the First Commercial Treatment of the OncoSilTM Device in Europe

OncoSil Medical Limited Announces Fully-Funded Trial Approval in Germany To Increase Sales of OncoSil Device

Price target increased to AU$0.17

First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Here's Why We're Watching OncoSil Medical's (ASX:OSL) Cash Burn Situation

Oncosil Medical Limited announces PanCO Clinical Study on OncoSil(TM) Published in ESMO Open

Less than half of directors are independent

Is OncoSil Medical (ASX:OSL) In A Good Position To Deliver On Growth Plans?

Full year 2021 earnings released: AU$0.013 loss per share (vs AU$0.006 loss in FY 2020)

OncoSil Medical Limited Provides Update on TGA Regulatory

OncoSil Medical (ASX:OSL) Is In A Good Position To Deliver On Growth Plans

OncoSil Medical's (ASX:OSL) Stock Price Has Reduced 42% In The Past Five Years

Analysts lower revenue estimates to AU$189.0k

Price target lowered to AU$0.34

First half 2021 earnings released: AU$0.006 loss per share (vs AU$0.005 loss in 1H 2020)

OncoSil Medical Limited Announces Executive Appointments

We're Not Worried About OncoSil Medical's (ASX:OSL) Cash Burn

OncoSil Medical Limited Appoints Nigel Lange as Chief Executive Officer

How Much Did OncoSil Medical's(ASX:OSL) Shareholders Earn From Share Price Movements Over The Last Year?

OncoSil Medical Limited Announces Executive Changes

OncoSil Medical Limited Receives Swiss Regulatory Approval

Independent Non-Executive Chairman recently bought AU$405k worth of stock

Analysts update estimates

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin